Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.70 |
| ▸ | GSK3A | P49840 | 13/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204989 | 0.84 | GSK3A (0.84) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20189799 | 0.83 | GSK3B (0.71) | GSK3BGSK3AMAPTATRPIM1 | |
| SCHEMBL20205218 | 0.83 | GSK3B (0.70) | GSK3BGSK3AMAPTCNR2JAK2 | |
| SCHEMBL20190158 | 0.83 | GSK3A (1.00) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20205036 | 0.82 | GSK3A (0.84) | GSK3BGSK3ACD38JAK2PIM1 | |
| SCHEMBL20205072 | 0.81 | GSK3A (0.83) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20205073 | 0.81 | GSK3A (0.83) | GSK3BGSK3AMAPTJAK2PIM1 | |
| SCHEMBL20205226 | 0.81 | GSK3B (0.68) | GSK3BGSK3AMAPTCNR2JAK2 | |
| SCHEMBL21461686 | 0.81 | GSK3A (0.70) | GSK3BGSK3ACNR2JAK2PIM1 | |
| SCHEMBL21461702 | 0.81 | GSK3A (0.70) | GSK3BGSK3AJAK2PIM1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110545817-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| CN-110545817-A | GSK-3 inhibitors | SQUIBB BRISTOL MYERS COMPANY | 2019-12-06 | — | — | CN | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3544613-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315714-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885EGFR 2441/4885 |
| US-10752609-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885EGFR 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.